Breaking News Instant updates and real-time market news.

TEVA

Teva

$14.62

-0.12 (-0.81%)

08:04
10/19/17
10/19
08:04
10/19/17
08:04

Teva to present data on MS program at joint ECTRIMS/ACTRIMS congress

Teva Pharmaceutical Industries announced that new data on its multiple sclerosis program, including COPAXONE, a product for relapsing forms of MS, and laquinimod, an investigational MS therapy, will be highlighted in 11 presentations at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis in Paris, October 25-28, 2017. In addition to the data being presented, Teva will also host a Satellite Symposium, "Maintaining ability in the context of disability: can we do more for patients?" on October 27, 2017 from 12:45 - 1:45 p.m. CET. COPAXONE is indicated for the treatment of patients with relapsing forms of multiple sclerosis. The most common side effects of COPAXONE are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. COPAXONE is rated as Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. Administration of glatiramer acetate by subcutaneous injection to pregnant rats and rabbits resulted in no adverse effects on offspring development.

  • 02

    Nov

TEVA Teva
$14.62

-0.12 (-0.81%)

10/16/17
WELS
10/16/17
NO CHANGE
WELS
Outperform
Court ruling looks 'clearly negative' for Allergan, says Wells Fargo
Wells Fargo analyst David Maris says a federal judge ruling today that Allergan's (AGN) Restasis patents are invalid "appears clearly negative" for the company. Due to the magnitude of the potential damages involved, however, an at-risk generic launch is unlikely, Maris tells investors in an intraday research note. As such, the analyst continues to believe the earliest that a generic version of Restasis may enter the market is sometime in 2019. Maris keeps an Outperform rating on Allergan. He adds that today's court ruling is incrementally positive for generic Restasis filers, if approved, including Teva (TEVA), Mylan ( MYL) and Akorn (AKRN).
10/13/17
WELS
10/13/17
NO CHANGE
Target $276
WELS
Outperform
Allergan settlement leaves three Restasis challengers, say Wells Fargo
Wells Fargo analyst David Maris says three Restasis generic challengers remain after Allergan (AGN) reached a settlement with InnoPharma. The settlement, which allows InnoPharma to launch a generic Restasis in the U.S. beginning February 24, 2024, or six months before the expiration of Allergan's patents, points to the complexity of Restasis and the difficulty of getting a generic version approved, Maris tells investors in a research note. InnoPharma was one of four included in a consolidated lawsuit against Allergan, with Teva (TEVA), Mylan (MYL) and Akorn (AKRX) remaining, Maris points out. He's encouraged that the settlement date reached with InnoPharma is close to the expiration date of the patents. The analyst keeps an Outperform rating on Allergan with a $276 price target.
10/04/17
JPMS
10/04/17
NO CHANGE
JPMS
Overweight
JPMorgan says generic Copaxone approval 'meaninful positive' for Mylan
Mylan's (MYL) generic Copaxone approval, 9-12 months ahead of investor expectations, represents a "meaningful positive" for the story and will "substantially derisk/support" upside to 2017 and 2018 estimates, JPMorgan analyst Chris Schott tells investors in a research note. The analyst reiterates an Overweight rating on the shares. For Teva (TEVA), the approval puts further pressure on the company's "already challenged" near-term earnings profile and delevering efforts, Schott writes. The analyst keeps a Neutral rating on the shares. The analyst believes the earlier than expected approval for Mylan represents a setback for Momenta Pharmaceuticals' (MNTA) generic Copaxone opportunity. Schott had assumed the company's Glatopa would be the first generic version of Copaxone 40mg to enter the market, but he notes the product has been delayed due to manufacturing issues at a Pfizer (PFE) plant handling fill/ for the drug. The analyst, however, continues to see a "large and fairly durable" generic opportunity for Glatopa. He keeps an Overweight rating on Momenta shares, which are down 27% in premarket trading to $12.75. Mylan is up 17% to $38.20 while Teva is down 15% to $15.95.
10/04/17
BTIG
10/04/17
NO CHANGE
BTIG
Mylan generic Copaxone sales could reach $450M in first year, says BTIG
BTIG analyst Timothy Chiang estimates that Mylan (MYL) could obtain up to $450M of sales from its generic version of Teva's (TEVA) Copaxone in the first year in which it is marketed. The analyst believes that the approval "validates" the company's status as a "premier" generic drugmaker and shows that one can never assume that it will lose a battle over generic drug rights. The analyst raised his price target on the shares to $45 from $42 and keeps a Buy rating on the stock.

TODAY'S FREE FLY STORIES

CAL

Caleres

$30.99

0.05 (0.16%)

16:20
11/21/17
11/21
16:20
11/21/17
16:20
Earnings
Caleres backs FY17 adjusted EPS view $2.10-$2.20, consensus $2.16 »

Backs FY17 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CAL

Caleres

$30.99

0.05 (0.16%)

16:19
11/21/17
11/21
16:19
11/21/17
16:19
Earnings
Caleres reports Q3 EPS 80c, consensus 85c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

ALEX

Alexander & Baldwin

$44.87

0.75 (1.70%)

16:18
11/21/17
11/21
16:18
11/21/17
16:18
Hot Stocks
Alexander & Baldwin announces sale of Midstate 99 Distribution Center for $33.4M »

Alexander & Baldwi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDU

MDU Resources

$26.89

0.24 (0.90%)

16:18
11/21/17
11/21
16:18
11/21/17
16:18
Hot Stocks
MDU Resources plans to increment CapEx up to $471M in FY20 »

MDU Resources Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$34.33

-0.31 (-0.89%)

, TWX

Time Warner

$89.53

1.82 (2.08%)

16:18
11/21/17
11/21
16:18
11/21/17
16:18
General news
On The Fly: Top stock stories for Tuesday »

Stocks opened sharply…

T

AT&T

$34.33

-0.31 (-0.89%)

TWX

Time Warner

$89.53

1.82 (2.08%)

GSK

GlaxoSmithKline

$34.81

-0.31 (-0.88%)

PFE

Pfizer

$35.54

0.19 (0.54%)

UA

Under Armour

$11.37

-0.7 (-5.80%)

UAA

Under Armour

$12.85

-0.59 (-4.39%)

JEC

Jacobs Engineering

$64.86

5.52 (9.30%)

OSUR

OraSure

$16.55

2.59 (18.55%)

CPB

Campbell Soup

$45.84

-4.09 (-8.19%)

DSW

DSW

$19.55

-2.98 (-13.23%)

SIG

Signet Jewelers

$52.79

-23.05 (-30.39%)

CYTK

Cytokinetics

$8.25

-2.85 (-25.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 28

    Nov

  • 29

    Nov

  • 07

    Dec

  • 07

    Dec

  • 08

    Dec

  • 14

    Dec

GES

Guess

$17.94

0.16 (0.90%)

16:18
11/21/17
11/21
16:18
11/21/17
16:18
Earnings
Guess raises FY18 adjusted EPS view to 56c-63c from 52c-60c, consensus 60c »

Narrows FY18 net revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

DRE

Duke Realty

$29.30

0.39 (1.35%)

16:17
11/21/17
11/21
16:17
11/21/17
16:17
Hot Stocks
Duke Realty declares 85c per share special dividend »

Duke Realty announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.80

1.43 (1.33%)

16:17
11/21/17
11/21
16:17
11/21/17
16:17
Earnings
Breaking Earnings news story on Salesforce »

Salesforce sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

$NSD

NASDAQ Market Internals

16:17
11/21/17
11/21
16:17
11/21/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GES

Guess

$17.94

0.16 (0.90%)

16:17
11/21/17
11/21
16:17
11/21/17
16:17
Earnings
Guess sees Q4 adjusted EPS 48c-55c, consensus 52c »

Sees Q4 revenue growth in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

GES

Guess

$17.94

0.16 (0.90%)

16:16
11/21/17
11/21
16:16
11/21/17
16:16
Earnings
Guess reports Q3 adjusted EPS 12c, consensus 12c »

Reports Q3 revenue $554M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

$NYE

NYSE Market Internals

16:16
11/21/17
11/21
16:16
11/21/17
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVA

Avista

$51.64

-0.19 (-0.37%)

16:14
11/21/17
11/21
16:14
11/21/17
16:14
Hot Stocks
Avista shareholders approve acquisition by Hydro One at $53 per share »

Avista Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

AXTA

Axalta Coating

$33.85

0.31 (0.92%)

, AKZOY

AkzoNobel

$30.57

0.085 (0.28%)

16:14
11/21/17
11/21
16:14
11/21/17
16:14
Periodicals
Axalta Coating, AkzoNobel abandon merger talks, WSJ says »

Axalta Coating (AXTA) and…

AXTA

Axalta Coating

$33.85

0.31 (0.92%)

AKZOY

AkzoNobel

$30.57

0.085 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.48

1.11 (1.03%)

16:12
11/21/17
11/21
16:12
11/21/17
16:12
Hot Stocks
Salesforce CEO: 'We're on a path to exceed $20 billion' »

"Salesforce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

CRM

Salesforce

$108.58

1.21 (1.13%)

16:11
11/21/17
11/21
16:11
11/21/17
16:11
Hot Stocks
Breaking Hot Stocks news story on Salesforce »

Salesforce reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

HPQ

HP Inc.

$22.45

0.33 (1.49%)

16:10
11/21/17
11/21
16:10
11/21/17
16:10
Hot Stocks
HP Inc. drops 6% in afterhours trading after earnings, guidance »

HP Inc. shares are down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CRM

Salesforce

$108.55

1.18 (1.10%)

16:10
11/21/17
11/21
16:10
11/21/17
16:10
Hot Stocks
Salesforce reports deferred revenue $4.39B, up 26% y/y »

Up 24% in constant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

HPE

HP Enterprise

$14.15

0.055 (0.39%)

16:09
11/21/17
11/21
16:09
11/21/17
16:09
Earnings
Breaking Earnings news story on HP Enterprise »

HP Enterprise backs FY18…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

  • 11

    Dec

GME

GameStop

$16.64

0.2 (1.22%)

16:09
11/21/17
11/21
16:09
11/21/17
16:09
Earnings
GameStop sees FY17 EPS $3.10-$3.40, consensus $3.31 »

Sees FY17 comparable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CRM

Salesforce

$108.45

1.0775 (1.00%)

16:09
11/21/17
11/21
16:09
11/21/17
16:09
Earnings
Salesforce sees FY19 revenue $12.45B-$12.5B »

An increase of 19%-20%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

QADB

QAD Inc

$31.74

1.74 (5.80%)

16:08
11/21/17
11/21
16:08
11/21/17
16:08
Earnings
QAD sees FY18 revenue $300M-$302M, consensus $294.59M »

FY18 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$22.46

0.335 (1.51%)

16:08
11/21/17
11/21
16:08
11/21/17
16:08
Hot Stocks
HP Inc. says results demonstrate HP 'strong and getting stronger' »

"Our results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CRM

Salesforce

$108.60

1.24 (1.16%)

16:08
11/21/17
11/21
16:08
11/21/17
16:08
Earnings
Salesforce raises FY18 adjusted EPS view to $1.32-$1.33 from $1.29-$1.31 »

FY18 consensus $1.32.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

HPE

HP Enterprise

$14.16

0.065 (0.46%)

16:08
11/21/17
11/21
16:08
11/21/17
16:08
Hot Stocks
HP Enterprise announces Antonio Neri to replace Meg Whitman as CEO »

Hewlett Packard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.